Introduction
============

Osteoarthritis (OA) is the most common of all joint diseases and exacts a heavy economic toll due to its high prevalence in the general population and potential for causing progressive disability.[@b1-oarrr-9-171] The etiology is multifactorial, including a variety of risk factors (aging, genetics, trauma, malalignment, and obesity) that interact to cause this disorder.[@b2-oarrr-9-171] The primary goal of treatment is the alleviation of pain, leading to an improvement in joint function and quality of life. Treatment options for knee OA include conservative measures, pharmacological treatments, intraarticular (IA) injections, and surgical intervention.[@b3-oarrr-9-171]

Viscosupplementation is a well-established treatment option in OA. Hyaluronic acid (HA) exerts a mechanical effect providing lubrication of the joint, protecting against loads and impacts, and restoring the rheological properties of the synovial fluid.[@b4-oarrr-9-171] HA also has a pharmacological effect by interacting with mediators of inflammation, inhibiting nociceptors of pain, stimulating chondrocyte growth, synthesis of extracellular matrix protein, and reduction of apoptosis in osteoarthritic cartilage.[@b5-oarrr-9-171]--[@b8-oarrr-9-171] HA products that are available differ in many characteristics, including origin (animal vs biofermentation), molecular weight (MW), structure (linear, crosslinked, and mix of both), volume of injection, and posology. Clinical investigations with these products have been mainly focused on the potential differences attributable to MW. Arbitrarily, different HA products have been divided into three MW categories: low (500--730 kDa), intermediate (800--2,000 kDa), and high MW (2,000--6,000 kDa) including crosslinked formulations of HA.[@b9-oarrr-9-171]

The therapeutic use of platelet-rich plasma (PRP) is based on the use of the patient's own platelets as carrier of growth factors and other proteins (eg, fibronectin and other adhesive proteins) that play an important role in cell biology. The resulting products vary in their leukocyte content, platelet concentration, subsequent activation, and, at this moment, it is not defined what should be the ideal concentration of platelets that should reach the preparations as well as the dosage regimen.[@b10-oarrr-9-171] Although it seems PRP may improve the symptomatology, one part of the scientific community considers that there still exists a lack of clarity in available evidence for this to be recommended in international guidelines.[@b11-oarrr-9-171]

Knee arthroscopy has become the gold standard in the diagnosis of meniscal and ligamentous injury[@b12-oarrr-9-171] and also plays a role in their management.[@b13-oarrr-9-171] This intervention has been widely used as a treatment for OA of the knee, but recent studies[@b14-oarrr-9-171]--[@b16-oarrr-9-171] with controversial design and methodology[@b17-oarrr-9-171] have questioned its usefulness. However, it should be noted that \>90% of patients with symptomatic knee OA have magnetic resonance imaging findings compatible with meniscal pathology.[@b18-oarrr-9-171] Therefore, arthroscopic surgery would be indicated in those patients with meniscal injuries, loose bodies, osteochondral lesions, or synovial pathology, with a concomitant diagnosis of knee OA playing an essential role in the adequate selection of patients who can benefit from this technique.[@b19-oarrr-9-171]

Arthroscopy has decreased morbidity as compared with that in open procedures, but it has not eliminated pain completely. The causative factors behind this persistent pain are unknown, although it is known that most of the IA structures of the knee, including the synovial tissue, the anterior fat pad, and the joint capsule, have free nerve endings that are capable of sensing painful stimuli and producing severe pain.[@b20-oarrr-9-171],[@b21-oarrr-9-171] Moreover, it has been postulated that the severity and extent of OA, the degree of debridement undertaken, and the skill of the surgeon could be factors involved.[@b22-oarrr-9-171]

Considering the abovementioned aspects, this study was planned as a pilot to assess the effectiveness of different treatments such as viscosupplementation or PRP as compared to standard care for pain relief after knee arthroscopic debridement in patients with meniscal pathology and OA, under normal clinical practice conditions.

Patients and methods
====================

Ethics
------

The study was conducted in accordance with the Good Clinical Practice guidelines and in compliance with the principles of the Declaration of Helsinki. The study protocol was approved by the local Ethics Review Board from Hospital Español de México, and all patients gave written informed consent to participate in the study.

Design
------

This was a prospective, randomized, evaluator-blind, pilot study with four parallel arms and a control group.

Eligible patients were informed about study purpose and design. Demographic characteristics and medical history of the participants were recorded, and laboratory tests were done. X-rays of both knees were performed using anteroposterior projection with support, lateral with 30° flexion, and Merchant (45°) views; bipodalic mechanical axis digitalization as well as magnetic resonance imaging of the affected knee were also done.

Arthroscopies were all carried out by a single orthopedic/arthroscopic surgeon. All patients were given three doses of antibiotic (cephalothin 1 g) as prophylaxis. Postsurgical pain treatment comprised oral acetaminophen 1 g/8 h and celecoxib 200 mg/12 h for 10 days.

After surgery, patients were randomized to receive: 1) five IA injections of HA1 (Suprahyal^®^/Adant^®^: biofermentation, non-crosslinked, 600--1,200 kDa, 25 mg/syringe); 2) four IA injections of HA2 (Orthovisc^®^: biofermentation, non-crosslinked, 1,700--2,900 kDa, 30 mg/syringe); 3) three IA injections of HA3 (Synvisc^®^: chicken combs, crosslinked, 7,000 kDa, 16 mg/syringe); 4) a single IA injection of PRP (GPS^®^ II); and 5) standard care. The HAs used were considered of interest as they have different characteristics, [@b23-oarrr-9-171], [@b24-oarrr-9-171] to study whether these differences could have any impact on the efficacy/safety results. The number of doses specified are those authorized for each product.[@b23-oarrr-9-171]

The GPS^®^ II is a closed system that enables PRP to be collected while avoiding the risk of contamination and makes possible to concentrate the autologous platelets for reinjection locally.[@b25-oarrr-9-171]

Eligible patients were randomized 1:1 using a computer-generated list of random numbers. The random sequence was created using freely accessible tools available at <http://www.randomization.com>, which uses the pseudo-random number generator of Wichmann and Hill, [@b26-oarrr-9-171] modified by McLeod.[@b27-oarrr-9-171]

PRP was administered immediately after arthroscopy and viscosupplements were given once a week, starting at 21 days post-arthroscopy. Rescue medication comprised acetaminophen 1 g/8 h and celecoxib 200 mg/12 h.

The administration of IA treatments was conducted under aseptic conditions, inserting the needle into the patellofemoral joint space by a superolateral approach, with the patients in a supine position. In case effusion was present, it was removed before each injection.

Follow-up was conducted by five orthopedic surgeons, each one assigned to a specific group and blinded to the treatment administered. Visits were scheduled at 3, 6, 12, and 18 months after arthroscopy.

All patients were prescribed the same protocol of rehabilitation to be followed at the patient's convenience. The rehabilitation protocol started progressively, starting with isometric exercises and muscle stretching from Week 1 post-arthroscopy, adding weight exercises from Week 3, cardiovascular training from Week 7, and high-impact exercises from 3 months onward.

Patient selection criteria
--------------------------

Eligible patients were men and women, aged 40--85, with body mass index (BMI) \<35 kg/m^2^, and indications for knee arthroscopic surgery due to symptomatic meniscal rupture Mink et al[@b28-oarrr-9-171] grade III confirmed by magnetic resonance imaging, radiographic OA grades I--II according to Kellgren and Lawrence (KL),[@b29-oarrr-9-171] meniscal preservation \>60%, ligament integrity, and ability and willingness to provide informed consent for study participation.

Main exclusion criteria were infectious conditions, use of anticoagulants, history of trauma (dislocation or fracture), inflammatory arthritis, microcrystalline arthropathies, history of septic arthritis, ligament injury, nonspecific synovitis, angular deformity \>10°, chondral lesions G-IV Outerbridge (\>1 cm^2^),[@b30-oarrr-9-171] neoplasms, or allergy to any of the components of the products under study.

Evaluation of efficacy
----------------------

Efficacy was evaluated using the Western Ontario McMaster University Osteoarthritis Index (WOMAC) total and subscales of pain, stiffness, and function using a five-point (0--4) Likert scale. Scores at the end of follow-up (18 months) were compared to baseline and the differences between treatment groups were analyzed. Secondary outcomes were efficacy rates at the different follow-up visits.

The WOMAC questionnaire used was the Spanish translated version from Batlle-Gualda et al,[@b31-oarrr-9-171] validated by Escobar et al.[@b32-oarrr-9-171] The number of patients achieving the Minimal Clinically Important Improvement (MCII) in each treatment group was also calculated. The MCII is the smallest change in measurement that signifies an important improvement in a patient's symptom.[@b33-oarrr-9-171] According to Tubach et al,[@b34-oarrr-9-171] a 15 out of 100 for absolute improvement and 20% for relative improvement could be used as cutoffs for MCII estimation. Taking into account that, in our study, a Likert scale was used, the 20% of relative improvement cutoff was applied.[@b33-oarrr-9-171]

Evaluation of safety
--------------------

The incidence and type of adverse events was recorded throughout the study.

Statistics
==========

Categorical variables were summarized by their number and relative frequencies. For continuous variables following a normal distribution (Kolmogorov--Smirnov test), mean, standard deviation, and maximum and minimum values were used. Non-normally distributed variables were summarized with their median, interquartile range, minimum, and maximum.

Changes in WOMAC total and subscales at 3, 6, 12, and 18 months were expressed as raw scores and as percentage of change from the baseline value. Comparisons between groups were done using chi-square test or Fisher's Exact test for categorical variables when necessary. Continuous data were analyzed using Mann--Whitney test.

The study was designed as a pilot evaluation; therefore, real sample-size estimation was not done.

The main population for analysis was the per protocol (PP) population, comprising patients who completed the 18 months follow-up according to the study protocol. Safety analysis was conducted in all patients who received at least one IA injection.

Data were analyzed using SPSS V14 (SPSS Inc, Chicago Il). All tests were two-sided, and the statistical significance was set at 0.05.

Results
=======

Disposition of patients and demographics
----------------------------------------

Patients were recruited from March 2013 to October 2014. Ninety patients were initially screened, of whom 40 were excluded due to age (n=4), history of trauma or ligament involvement (n=5), overweight (n=6), meniscal injury \> 40% (n=4), chondral lesions G-IV (Outerbridge \>1 cm^2^; n=5), eventual total knee arthroplasty (TKA) (n=7), lost to follow-up (n=8), or death unrelated to the study (n=1), leaving a total of 50 patients who participated in the study and completed all procedures as scheduled ([Figure 1](#f1-oarrr-9-171){ref-type="fig"}).

Among study subjects, 52% were male and the mean age was 64.4 years, with statistically significant differences between HA2 and HA3 (*p*=0.007). Mean BMI was 27.8 kg/m^2^ without differences among groups (*p*=0.693), despite HA2 comprising more obese patients ([Table 1](#t1-oarrr-9-171){ref-type="table"}).

Near all patients in the HA3 group had mild OA (KL grade I), with the differences significant versus HA2 (*p*=0.001) and control (*p*=0.002). The groups were homogeneous with respect to WOMAC total values (*p*=0.062) as well as pain (*p*=0.234), stiffness (*p*=0. 383), and function (*p*=0.089) subscales ([Table 1](#t1-oarrr-9-171){ref-type="table"}).

There were no differences among groups in arthroscopic lesions ([Table 2](#t2-oarrr-9-171){ref-type="table"}). The following surgical procedures were conducted: partial meniscectomy of no more than 40% (35 patients), synovectomy and resection of Hoffa's fat pad (five patients), and debridement and stabilization of the chondral lesion (16 patients). More than one procedure in the same patient was possible.

Efficacy
========

At early follow-up (3 months), total WOMAC scores improved as compared to baseline, in all groups with reductions of 44.79% (HA1), 24.0% (HA2), 40.38% (HA3), 39.77% (PRP), and 27.64% (control), (*p*=0.002 HA1 compared to HA2).

At 18 months, a higher improvement in total WOMAC was observed in HA1 with a 65.20% reduction, followed by PRP (55.01%), HA3 (49.57%), and HA2 (29.82%), whereas the control group had a 14.5% increase over baseline despite the use of rescue medication and rehabilitation, with the differences statistically significant with respect to HA1 and HA3 (*p*=0.001; [Table 3](#t3-oarrr-9-171){ref-type="table"} and [Figures 2A--D](#f2-oarrr-9-171){ref-type="fig"}).

At 3 months follow-up, the percentage of patients achieving the MCII for both pain and function (20% of relative change) in different groups was 80% (HA1), 20% (HA2), 40% (HA3), 30% PRP, and 30% (control). At the end of follow-up, a growing number of patients experienced a clinically significant improvement in HA1 with a 100% responders rate, followed by HA3 (80%). In the group treated with HA2 and in those treated with PRP, the results reached 60% responders, whereas in the control group, all patients returned to near pre-arthroscopy levels of pain and impairment and none of the patients reached the 20% MCII cutoff ([Figure 3](#f3-oarrr-9-171){ref-type="fig"}).

Safety
======

Throughout the overall study period, patients did not experience adverse events attributable to surgery or to IA injections.

Discussion
==========

Arthroscopic surgery is frequently advocated as a treatment option to relieve symptoms of painful degenerative knee conditions. The rationale is that it may improve symptom and functions, has minimal morbidity, provides a therapeutic options, and documents the stage of the disease process. The duration of effect, however, is variable.[@b35-oarrr-9-171] Adjunctive therapies such as nonsteroidal anti-inflammatory drugs and other medications, physiotherapy, and IA steroid injections may be incorporated to improve the results.[@b36-oarrr-9-171],[@b37-oarrr-9-171]

The use of arthroscopic surgery in the treatment of OA has generated much discussion. Whereas some studies[@b14-oarrr-9-171],[@b15-oarrr-9-171] reported no differences with placebo arthroscopy, other studies confirm that, in patients with preoperative mechanical symptoms secondary to loose bodies, chondral flaps, and meniscal pathology, the use of arthroscopic surgery is beneficial.[@b38-oarrr-9-171],[@b39-oarrr-9-171] The key point is to offer knee arthroscopy to selected patients. Patients with symptomatic meniscal tears, few degenerative changes, normal axis, and acute mechanical complaints can benefit from this intervention, especially if the OA is mild or moderate.[@b40-oarrr-9-171]--[@b42-oarrr-9-171] Favorable results have been also shown for the management of the infrapatellar fat pad impingement and Hoffa's disease.[@b43-oarrr-9-171],[@b44-oarrr-9-171] Chronic complaints, previous surgical intervention, degenerative changes in two or three compartments, significant axis deviation, ligament imbalance, or severe cartilage destruction are among the characteristics of patients who may be candidates for unsatisfactory results after arthroscopy.[@b42-oarrr-9-171]

As a result, arthroscopic knee surgery is the most common type of orthopedic surgery performed in the developed world.[@b45-oarrr-9-171] However, in patients with symptomatic OA, pain can persist after arthroscopic meniscectomy and/or debridement of chondral lesions.

Treatment combining arthroscopic surgery and viscosupplementation has been widely used for patients with combined intraarticular mechanical and articular surface pathology.[@b40-oarrr-9-171] Initially, rheological characteristics that confer a lubricating effect to HA were considered the primary mechanism of action in treating OA pain. Nevertheless, rather than being a mere device, HA has been shown to exert other effects such as inhibition of tissue nociceptors, inhibition of matrix metalloproteinases, free radicals scavenging, and stimulation of endogenous HA production. Due to this, viscosupplementation has been recommended as adjunctive therapy after arthroscopic surgery as a suitable way of achieving long-term stabilization of the treatment outcome.[@b40-oarrr-9-171],[@b44-oarrr-9-171],[@b46-oarrr-9-171]

The application of PRP to patients with OA was developed because of the physiological roles of several bioactive proteins and growth factors expressed in platelets, which lead to tissue regeneration. Despite the use of PRPs having been extended to the treatment of several musculoskeletal injuries the last few years, we have not found published studies analyzing the efficacy of PRP as adjunctive treatment in post-arthroscopy patients. A recent meta-analysis found that at 6 months post injection, PRP and HA had similar effects with respect to pain relief and functional impairment. However, at 12 months, PRP was associated with better improvement scores.[@b47-oarrr-9-171]

In our study, the indication for knee arthroscopy was symptomatic rupture of a meniscus with symptomatic osteochondral detachment in patients with grade II OA. In these patients, surgery is the only and necessary indication, and they were given additional IA treatment with hyaluronate or PRP due to the presence of OA. In the market, there are a variety of HAs and our aim has been to verify if the differences between HA products has any clinical relevance, as well as to study the effects of PRP after knee arthroscopic debridement. Procedures for clinical practice and the dosage described by the manufacturers have been used; according to the studies published, treatments with HA usually started 3 weeks after surgery.[@b3-oarrr-9-171],[@b35-oarrr-9-171],[@b44-oarrr-9-171],[@b48-oarrr-9-171],[@b49-oarrr-9-171] In absence of recommendations in the literature, PRP injection was administered immediately after arthroscopy.

The HA1 product showed the best results, with a very significant improvement of the symptomatology compared to the baseline that was maintained up to 18 months post-arthroscopy (reduction of −65.20% in total WOMAC) and with 100% of the patients reaching the MCII 20% in pain and function, followed by HA3 with a reduction of −49.57 in total WOMAC and 80% of patients reaching the 20% MCII cutoff. These products differ in origin, MW, structure, and number of injections administered and, in our study, the differences between both did not reach statistical significance. However, it should be noted that 8/10 patients in the HA3 group were KL grade I, which is associated with better response data.[@b40-oarrr-9-171],[@b41-oarrr-9-171] The HA2 group showed much more discreet and erratic results, with final reduction in WOMAC at the end of the study and nearly 30% and 60% of patients complying with MCII requirements. It should be noted that, in this group, all patients had OA grade II as well as a greater number of overweight/obese patients -- a characteristic that may also have influenced the results.[@b44-oarrr-9-171]

A recent meta-analysis found that, at 6 months post injection, PRP and HA had similar effects with respect to pain relief and functional impairment. However, at 12 months, PRP was associated with better improvement scores.[@b47-oarrr-9-171] In our study, patients treated with PRP constitute a diverse group who seem to follow the rule of all or nothing, so that those who improve do so in a very significant way and this improvement is maintained until the end of follow-up, whereas something similar occurs with non-responder patients; thus, at the end of the study, only 60% of patients achieved the MCII threshold. Ayhan et al[@b50-oarrr-9-171] suggest that PRP therapy would be indicated for patients \<60 years and with a BMI \<30. In our study, the best results in the PRP group were also seen in patients with a BMI \<30, as well as in those \<60 years. We did not find any another relationship between the type of response and the characteristics of the patients or the arthroscopic findings.

Surprisingly, the control group showed low improvement in symptomatology at early follow-up that worsened along time with return to pre-arthroscopy levels at the 12-month follow-up that required the consumption of rescue medication.

One of the weaknesses of our study is the small sample size as it was designed as a pilot evaluation with the limitations that it entails when establishing comparisons; moreover, the fact that each group was evaluated by a different person may have influenced the evaluation of the results. Finally, not all patients undertook the rehabilitation protocol in the same way, as they were treated by different people and in different clinics according to the personal needs of the patient: a more strict control of this procedure would have been desirable. In our favor, the long follow-up period allowed us to assess the evolution of the results in the long term; the criteria used for patient selection was of special relevance to select those who may benefit most from the procedure, as was the presence of a control group. The design of the study also allowed us to study the behavior of three different HAs used within routine practice and to compare them with PRP as a new therapeutic approach.

Viscosupplementation is an effective treatment for the treatment of knee OA. Based on our results, we consider that its use in combination with arthroscopic surgery can provide very good results in adequately selected patients with an individualized and multidisciplinary follow-up. However, due to the importance of this type of intervention, further controlled studies with a larger sample size and/or alternative posology regimens would be of interest for the scientific community.

The authors thank Juan J. Granizo (Granadatos S.L.) for the statistical analysis of the results.
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WOMAC Total **(A)**, *p* values: 3 months: HA1 vs HA2=0.002; 6 months: HA1 vs HA2=0.001; HA2 vs HA3=0.001; 12 months: HA1 vs Control=0.031; HA3 vs Control=0.046; and 18 months: HA1 vs Control=0.001; HA3 vs Control=0.003. WOMAC Pain **(B)**, *p* values: 3 months: NS differences; 6 months: HA1 vs Control=0.026; HA1 vs HA2=0.002; 12 months: HA1 vs Control=0.012; HA1 vs HA2=0.008; HA3 vs Control=0.004; and 18 months: HA1 vs Control=0.001; HA2 vs Control=0.030; HA3 vs Control=0.003. WOMAC stiffness **(C)**, *p* values: 3 months: HA1 vs Control: 0.001; HA3 vs Control: 0.038; 6 months: HA1 vs Control: 0.003; 12 months: HA1 vs Control: 0.001; HA3 vs Control: 0.010; and 18 months: HA1 vs Control: 0.002. WOMAC Function **(D)**, *p* values: 3 months: HA1 vs HA2: 0.006; 6 months: HA1 vs HA2=0.002; HA3 vs HA2=0.001; 12 months: HA1 vs Control=0.050: HA3 vs Control=0.049; and 18 months: HA1 vs Control=0.002.\
**Abbreviations:** PRP, platelet-rich plasma; WOMAC, Western Ontario and McMaster Universities Arthritis Index.](oarrr-9-171Fig2){#f2-oarrr-9-171}
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###### 

Demographics and baseline condition of study groups

  -----------------------------------------------------------------------------------------------------------------------------------------
                     HA1\            HA2\           HA3\            PRP\            Control\        Total\       *p*
                     (n=10)          (n=10)         (n=10)          (n=10)          (n=10)          (n=50)       
  ------------------ --------------- -------------- --------------- --------------- --------------- ------------ --------------------------
  Sex M, n (%)       7 (70.0)        4 (40.0)       6 (60.0)        4 (40.0)        5 (50.0)        26 (52.0)    ns

  Age, mean (SD)     66.3 (9.6)      71.1 (7.0)     56.9 (9.8)      60.3 (9.5)      67.5 (7.8)      64.4 (9.9)   HA2 vs HA3 *p*=0.007

  Age distribution                                                                                               

  ≤65                5               1              7               6               4               23 (46%)     

  \>65               5               9              3               4               6               27 (54%)     

  BMI, mean (SD)     26.6 (3.2)      28.9 (3.0)     27.6 (2.8)      28.0 (3.6)      28.1 (3.2)      27.8 (3.1)   ns

  BMI distribution                                                                                               

  ≤24.9              3               1              1               1               1               7 (14%)      

  ≥25-- \>29.9       5               3              6               6               5               25 (50%)     

  ≥30-- \>34.9       2               6              3               3               4               18 (36%)     

  Grade II K&L (%)   6 (60.0)        10 (100.0)     2 (20.0)        6 (60.0)        9 (90.0)        33 (66.0)    HA2 vs HA3 *p*=0.001\
                                                                                                                 HA3 vs Control *p*=0.002

  WOMAC, mean (SD)                                                                                               

  Total              52.40 (20.40)   67.00 (4.42)   56.60 (17.58)   54.80 (11.26)   65.10 (12.73)   --           ns

  Pain               14.30 (4.11)    15.80 (3.05)   15.50 (1.90)    13.40 (3.03)    13.00 (4.24)    --           ns

  Stiffness          5.30 (1.89)     3.80 (1.93)    5.30 (1.89)     5.00 (2.16)     5.10 (2.28)     --           ns

  Function           32.80 (18.96)   47.40 (6,56)   32.90 (17.57)   36.40 (13.16)   49.20 (12.34)   --           ns
  -----------------------------------------------------------------------------------------------------------------------------------------

**Abbreviations:** PRP, platelet-rich plasma; WOMAC, Western Ontario and McMaster Universities Arthritis Index.

###### 

Type of lesion

  ----------------------------------------------------------------------------------------------------
  Localization, n (%)   HA1\       HA2\       HA3\       PRP\       Control\   *p*-value   Total\
                        (n=10)     (n=10)     (n=10)     (n=10)     (n=10)                 (n=50)
  --------------------- ---------- ---------- ---------- ---------- ---------- ----------- -----------
  Lateral meniscus      2 (20.0)   4 (40.0)   4 (40.0)   2 (20.0)   3 (30.0)   ns          15 (30.0)

  Medial meniscus       6 (60.0)   6 (60.0)   5 (50.0)   2 (20.0)   4 (40.0)   ns          23 (46.0)

  Synovitis             10 (100)   7 (70.0)   8 (80.0)   10 (100)   9 (90.0)   ns          44 (88.0)

  Hoffitis              9 (90.0)   10 (100)   10 (100)   8 (80.0)   8 (80.0)   ns          45 (90.0)

  Lateral condyle       1 (10.0)   5 (50.0)   1 (10.0)   4 (40.0)   2 (20.0)   ns          13 (26.0)

  Patellofemoral        1 (10.0)   2 (20.0)   1 (10.0)   2 (20.0)   0 (0.0)    ns          6 (12.0)
  ----------------------------------------------------------------------------------------------------

**Abbreviation:** PRP, platelet-rich plasma.

###### 

Evolution of total WOMAC expressed as raw data and relative change at follow-up visits in treatment groups.

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  WOMAC Total, mean (SD)   HA1             HA2              HA3             PRP              Control         *p*-value                                                                          
  ------------------------ --------------- ---------------- --------------- ---------------- --------------- ---------------- --------------- ---------------- --------------- ---------------- ------------------------
  3 months                 29.80 (13.45)   −44.79 (8.33)    50.60 (5.87)    −24.02 (11.42)   35.20 (13.91)   −40.38 (13.29)   34.20 (24.28)   −39.77 (36.30)   44.00 (3.94)    −27.64 (28.00)   HA1 vs HA2: 0.002

  6 months                 20.00 (12.01)   −65.23 (10.37)   52.40 (7.32)    −20.87 (16.55)   19.00 (7.86)    −66.28 (11.30)   30.40 (29.74)   −47.55 (47.08)   37.00 (11.90)   −36.12 (44.09)   HA1 vs HA2: 0.001\
                                                                                                                                                                                                HA3 vs HA2: 0.001

  12 months                17.20 (13.07)   −71.79 (14.91)   51.40 (27.46)   −21.44 (45.94)   18.60 (8.55)    −67.12 (12.82)   30.00 (35.11)   −48.84 58.11     53.50 (16.50)   −10.28 50.08     HA1 vs Control: 0.001\
                                                                                                                                                                                                HA3 vs Control: 0.001

  18 months                17.60 (7.23)    −65.20 (8.89)    46.30 (25.88)   −29.82 (41.74)   25.00 (3.33)    −49.57 (22.72)   27.00 (36.75)   −55.01 (58.85)   70.50 (4.37)    14.55 (36.45)    HA1 vs Control: 0.001\
                                                                                                                                                                                                HA3 vs Control: 0.001
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Abbreviations:** PRP, platelet-rich plasma; WOMAC, Western Ontario and McMaster Universities Arthritis Index.
